Cargando...

A retrospective study of skeletal and disease-free survival benefits of zoledronic acid therapy in patients with multiple myeloma treated with novel agents

Background: The large majority of patients with multiple myeloma develop bone lesions and typically receive bisphosphonates to maintain bone health and prevent/delay skeletal-related events. Recent clinical data show that the newer-generation bisphosphonate, zoledronic acid, may confer a survival be...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Ria, Roberto, Reale, Antonia, Moschetta, Michele, Mangialardi, Giuseppe, Dammacco, Franco, Vacca, Angelo
Formato: Artigo
Idioma:Inglês
Publicado: e-Century Publishing Corporation 2012
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3515976/
https://ncbi.nlm.nih.gov/pubmed/23236556
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!